Tuesday, April 28, 2015

Our Expert Picks: Critical Data From EASL‏ 2015

2015 Meeting of the European Association for the Study of the Liver
Independent Conference Coverage*

Jordan J. Feld, MD, MPH
Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF
Andrew J. Muir, MD
David R. Nelson, MD
Norah Terrault, MD, MPH
Stefan Zeuzem, MD

The Capsule Summaries of the most important studies, as selected by the faculty members, are still being posted; the following are available to date.

Review Conference Coverage

Coming Soon: CME-certified Expert Analysis: Leading experts discuss the clinical implications of new data from the meeting in Vienna, Austria

Free registration is required

Capsule Summaries:

C-EDGE: Grazoprevir/Elbasvir Highly Effective in Treatment-Naive Patients With Genotype
1, 4, or 6 HCV Infection
High efficacy observed regardless of presence of cirrhosis, although patients with high baseline HCV RNA level were more likely to experience virologic failure.
Read More

ION-4: 96% SVR12 Rate With LDV/SOF for 12 Weeks in Patients Coinfected With HIV and Genotype 1 or 4 HCV
In multivariate analysis, black race only factor associated with treatment failure.
Read More

C-EDGE COINFECTION: 12 Weeks of Grazoprevir/Elbasvir Safe and Highly Effective in Genotype 1 and 4 HCV/HIV-Coinfected Patients
No HCV genotype/subtype or other patient parameter was associated with a decrease in treatment efficacy for this coinfected population.
Read More

High SVR12 Rate With Ledipasvir/Sofosbuvir Plus Ribavirin for 12 or 24 Weeks in GT1 or 4
HCV-Infected Patients With Decompensated Cirrhosis or HCV Recurrence After Liver Transplantation
In this population of patients with advanced liver disease, ledipasvir/sofosbuvir plus ribavirin treatment was generally safe and well tolerated with low rates of treatment-related serious adverse events and treatment discontinuation due to adverse events.
Read More

HCV-TARGET: High SVR12 Rates but More Frequent AEs Among Patients With Renal Dysfunction Treated With Sofosbuvir-Containing Regimens in Real-World Analysis
Rates of anemia-related AEs, worsening renal function, and renal and urinary AEs increased across patient groups with decreasing renal function.
Read More

C-SALVAGE: High SVR12 Rate Following 12 Weeks of Grazoprevir, Elbasvir, and Ribavirin in GT1 PI-Experienced Patients
The SVR12 rate in this PI-experienced population was 96% overall and 95% among patients with previous virologic failure; 3 patients relapsed with treatment-emergent NS3 and NS5A RAVs.
Read More

SVR12 in 71% of GT1 Patients Receiving 24 Weeks of Ledipasvir/Sofosbuvir Following Previous Treatment Failure With 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Therapy
In this open-label trial, SVR12 rates were numerically lower in patients with vs without baseline NS5A RAVs and in patients who received 12 vs 8 weeks of previous ledipasvir/sofosbuvir-based therapy.
Read More

C-SCAPE: 12-Week Grazoprevir/Elbasvir Plus RBV Demonstrates Efficacy in Patients With Genotype 2 HCV Infection in Phase II Study
Efficacy also observed in genotype 4 HCV-infected patients receiving grazoprevir/elbasvir with or without ribavirin; evaluation of efficacy in genotypes 5 and 6 require additional patient numbers.
Read More

Sofosbuvir Plus Ledipasvir or Daclatasvir With or Without Ribavirin Effective in Patients With HCV Genotypes 1 and 3 and Decompensated Cirrhosis
In this observational cohort study, higher SVR12 rates with 12 weeks of sofosbuvir plus daclatasvir than sofosbuvir/ledipasvir among patients with genotype 3 HCV infection.
Read More

Interim Analysis: Early Efficacy With Sofosbuvir Plus Daclatasvir With or Without Ribavirin in Cirrhotic Patients With Genotype 3 HCV in Compassionate Use Program
In the subset of study patients who have reached SVR4, extended treatment duration of 24 weeks appeared to provide greater efficacy vs 12 weeks in this difficult-to-treat population.
Read More

High Incidence of HCV Reinfection Following SVR Among Patients Who Relapse to Injection Drug Use
Incidence of HCV reinfection 4.7/100 person-years among patients who relapsed to injection drug use vs 1.8/100 person-years among those with any previous injection drug use.
Read More

These Capsule Summaries are part of the program:
Clinical Impact of New Data From EASL 2015 clinicaloptions.com/vienna2015.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

No comments:

Post a Comment